Key Stats for Pfizer Stock
- Current Price: $24.32
- Target Price (Mid): ~$28
- Street Target (Mean): ~$29
- Potential Total Return: ~14% (over 4.5 years, mid case)
- Annualized IRR: ~3% / year (mid case)
- Earnings Reaction: +0.30% (May 5, 2026)
- Max Drawdown: -17.09% (June 25, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Pfizer Inc. (PFE) has become the cheapest large name in its industry, and the market cannot agree on whether that is a bargain or a verdict. The stock sits at $24.32, a hair above its 52-week low of $23.11 and a long way from the $28.75 it touched over the past year. At that price, Pfizer trades at 8.5x next-twelve-month earnings. The median pharmaceutical peer trades at 16.4x. A gap that wide is not a rounding error. It is the market pricing in something specific, and investors are right to ask what.
The bulls have a clean story. You are paying half the industry multiple for a company with a 7% dividend, a rebuilt commercial engine, and a pipeline that is finally producing approvals. The bears have an equally clean story. The base business is shrinking, the COVID franchise keeps fading, and the biggest oncology readout of the year just missed. The one question neither side can settle yet: does the discount reflect a company in permanent decline, or one trading at a trough right before an inflection it has clearly telegraphed?
Why the market marked Pfizer down
The discount did not appear by accident. Two catalysts landed within days of each other in late June and captured the whole debate. On June 22, Pfizer disclosed that its Phase 3 SigVie-002 trial for sigvotatug vedotin, an antibody-drug conjugate (a targeted cancer therapy that delivers a toxic payload directly to tumor cells), missed its primary endpoint of overall survival in previously treated non-small cell lung cancer, the most common form of lung cancer. This was the readout the Street had flagged for months as the clearest near-term test of Pfizer’s oncology pipeline. It failed the headline test, though the company noted a stronger survival trend in second-line patients that keeps earlier-line studies alive.
Two days later, on June 24, the FDA approved an expanded use of Ibrance in combination with trastuzumab for HR-positive, HER2-positive metastatic breast cancer, making it the first and only CDK4/6 inhibitor cleared as a maintenance option in that setting. A win and a loss in the same week. The stock barely moved on either, drifting near its lows, which tells you the market had already decided to wait for proof rather than trade the headlines.
That standoff is the real reason the multiple compressed. Investors are not disputing that Pfizer has assets. They are disputing the timing of when those assets start growing revenue again.
See historical and forward estimates for Pfizer stock (It’s free!) >>>
What the discount is actually pricing
Here is where the peer comparison earns its place. Against its pharmaceutical peer group, Pfizer’s 8.5x forward earnings multiple sits below Bristol-Myers Squibb at 9.5x, Sanofi at 8.8x, Novo Nordisk at 16.4x, and Johnson & Johnson at 22.3x. The middle of that group prices at 16.4x, and Pfizer sits at the very bottom of it. On enterprise value to revenue, a measure comparing a company’s total value to its sales, Pfizer trades at 3.1x versus a peer median of 3.5x. The market is assigning Pfizer the lowest earnings multiple in its cohort, and the reason is growth, not quality.
Pfizer’s forward two-year revenue is expected to shrink at around a 2.6% annual rate, per TIKR estimates. That is the number doing the damage. A company losing revenue does not earn a market multiple, no matter how strong its balance sheet or how rich its yield. The 7% dividend functions as an income floor rather than a growth signal. That yield widened from 6.5% to 7.1% in a single quarter, mostly because the price fell, not because the payout grew. Investors reading the yield as a reward should read it as compensation for waiting instead.
The competitive backdrop cuts both ways. Eli Lilly, trading at 32.5x forward earnings, sits in a different universe because its obesity franchise is compounding revenue north of 30% a year. Pfizer is trying to reach that same market through its own monthly GLP-1 program, berobenatide, but launch is not expected until 2028. Until then, the discount to Lilly is not a mispricing. It is an accurate read of two companies at opposite ends of the growth cycle.
What management says changes after 2028
This is where the transcript matters more than the tape. At the Goldman Sachs Global Healthcare Conference on June 8, 2026, CEO Albert Bourla laid out the most specific version yet of why he believes the trough reverses. His argument was not a vision statement. It was a bottom-up bridge.
“I’m highly convinced about that. And this is not a vision statement,” Bourla said of Pfizer’s guidance for high-single-digit revenue growth beginning in 2029. He broke the case into three parts: in-line products with predictable trajectories, losses of exclusivity that the company can model precisely, and a risk-adjusted pipeline broad enough that individual failures wash out statistically. That last point matters directly for the SigVie miss. When one program of many fails, the bottom-up math still holds. That is the entire design of the argument.
Bourla also pointed to momentum already visible in the numbers. “Our new launches and business development business grew 22% this quarter at $3 billion,” he noted, describing a roughly $12 billion annualized business growing quickly enough to offset part of the patent cliff. Why it matters: this is the offset the bear case tends to ignore. The launched and acquired portfolio is not a promise; it is already producing revenue at a growth rate the base business cannot match.
The tension Bourla cannot resolve from a conference stage is proof. The market has heard the 2029 story. What it wants is a clinical or commercial result that validates the pipeline before then, and the SigVie miss pushed that proof point further out.
See how Pfizer performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $24.32
- Target Price (Mid): ~$28
- Potential Total Return: ~14%
- Annualized IRR: ~3% / year
See analysts’ growth forecasts and price targets for Pfizer stock (It’s free!) >>>
The TIKR mid-case model, realized at year-end 2030, values Pfizer at around $28, implying roughly 14% total return and about a 3% annualized IRR over 4.5 years. That is a modest return that leans heavily on the dividend rather than price appreciation. The two revenue drivers that define the case are the launched and acquired product portfolio, growing around 22%, and the risk-adjusted pipeline contribution weighted toward 2028 and beyond. The margin driver is continued cost discipline, with AI-enabled productivity holding net income margin near 25% even as revenue stays soft. The primary risk is the loss-of-exclusivity wave running through 2028, which the model treats as the known negative.
The upside: if the pipeline delivers even one blockbuster-scale validation, the model’s longer-horizon high case prices PFE will be meaningfully higher on both faster revenue and multiple expansion from today’s depressed 8.5x.
The downside: if the patent cliff bites harder than modeled and no new program scales, the discount is not a trap being sprung; it is a fair price for a business in slow decline.
Conclusion
The discount is real, but the catalyst that closes it is specific. Watch Pfizer’s second-quarter results, expected in late July or early August. The most important line is not the EPS print, which the flat estimates already anticipate. It is whether management reaffirms the $2.80 to $3.00 full-year adjusted EPS guidance and offers any concrete timeline update on the berobenatide obesity program or the earlier-line sigvotatug studies. That report also arrives around a planned leadership change, with CFO Dave Denton departing August 15 in a move Pfizer says is unrelated to its results, and Cecile Guegan stepping in as interim CFO the next day. A reaffirmed guide with a firm obesity timeline is the “good” outcome that starts validating the 2029 bridge. A trimmed guide or a pushed pipeline date is the “bad” outcome that confirms the bears. The 8.5x multiple will not move on sentiment. It moves on proof.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
